Global Leading Market Research Publisher QYResearch announces the release of its latest report “Euryale Ferox Extract – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Euryale Ferox Extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
For nutraceutical formulators, TCM pharmaceutical manufacturers, and functional food developers, the central challenge remains sourcing botanical extracts with documented traditional use and modern scientific validation for digestive and renal health applications. Euryale ferox extract directly addresses this need as a versatile aquatic seed-derived ingredient, prized in traditional Chinese medicine for its spleen-strengthening, kidney-tonifying, and Qi-invigorating properties. As of Q2 2025, consumer demand for natural digestive health solutions and kidney-support supplements has accelerated adoption of Euryale ferox-based formulations, particularly in China’s rapidly aging population segment, where renal health concerns are increasingly prevalent.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4939598/euryale-ferox-extract
Market Size & Growth Trajectory (2024–2031)
The global market for Euryale Ferox Extract was estimated to be worth US$ 70.00 million in 2024 and is forecast to a readjusted size of US$ 103 million by 2031 with a CAGR of 5.6% during the forecast period 2025-2031. In 2024, global production of Euryale ferox extract reached approximately 2,800 metric tons, with an average selling price varying by purity grade, extraction method, and product form (powder vs. liquid). This moderate but stable growth reflects the ingredient’s established position in TCM formulations and expanding applications in modern nutraceuticals. China dominates both production and consumption, accounting for approximately 85-90% of global volume, with primary production concentrated in Jiangsu, Hunan, and Guangdong provinces—regions with suitable aquatic cultivation environments.
Product Definition and Bioactive Composition
Euryale ferox extract is derived from the seeds of Euryale ferox Salisb., an aquatic plant belonging to the Nymphaeaceae family (water lily family), commonly known as fox nut or makhana. The extract is manufactured through processes including seed dehulling, milling, extraction (typically water or ethanol-based), filtration, concentration, and drying. It is rich in carbohydrates (primarily starches), amino acids (including essential amino acids), and polyphenolic compounds (such as gallic acid, ellagic acid, and catechin derivatives). This extract boasts benefits such as strengthening the spleen and kidneys, invigorating Qi and relieving diarrhea, and promoting dampness and leukorrhea reduction. It is widely used in pharmaceuticals, health products, and food. Modern research has demonstrated antioxidant and renal protection properties, with studies indicating that Euryale ferox polyphenols scavenge free radicals and reduce oxidative stress markers in renal tissue.
Key Industry Characteristics and Market Drivers
Concentrated Production Hub and Supply Chain Dynamics
The Euryale ferox extract market is characterized by a highly concentrated production footprint in China, with key players including Shaanxi New Horizon Biotechnology, Xian Tianxingjian Natural Bio-products, Ciyuan Biology, Xi’an Jincuifang Plant Technology Development, Shaanxi Yongyuan Biotechnology, World-Way Biotech, Sanyuan Tianyu Biological Products, Shaanxi Evergreen Herbal Biotech, Baoji Uupanyun Biology, Xian Clover Biotechnology, and Shaanxi Sinuote Biotechnology. Similar to other botanical extracts, production is heavily concentrated in Shaanxi Province—China’s botanical extraction hub—which enables supply chain efficiencies but creates vulnerability to regional regulatory changes. As of 2025, approximately 65% of Euryale ferox extract production capacity is located in Shaanxi, with manufacturers increasingly investing in GMP certification and export-ready facilities.
Upstream Cultivation: Aquatic Agriculture and Harvesting Challenges
Unlike terrestrial botanicals, Euryale ferox is cultivated in freshwater ponds, lakes, and wetlands. Major cultivation regions include Jiangsu Province (particularly the Taihu Lake area), Hunan Province, and Guangdong Province. The plant produces large prickly seed heads, with each head containing 20-50 seeds. Harvesting is labor-intensive, typically conducted manually during late summer to early autumn. In 2024, China’s Ministry of Agriculture and Rural Affairs issued guidelines for standardized aquatic botanical cultivation, encouraging integrated pest management and water quality monitoring for Euryale ferox farms. Total cultivated area reached approximately 45,000 hectares by early 2025, with yields averaging 1.2-1.8 tons of dried seeds per hectare. Climate variability—particularly extreme rainfall and temperature fluctuations during flowering—remains a significant supply risk, with the 2024 harvest 8% below 2023 levels due to unseasonal flooding in key producing regions.
Extraction Technology and Quality Parameter Challenges
From a technical standpoint, three critical challenges have emerged in 2025: (1) polyphenol preservation—conventional hot water extraction achieves only 40-50% recovery of heat-sensitive polyphenols, while cold extraction methods achieve 70-75% recovery but require longer processing times; (2) starch interference, as Euryale ferox seeds contain 60-70% starch by weight, complicating filtration and concentration steps; and (3) standardization of bioactive markers, with current Chinese Pharmacopoeia specifications lacking specific compound-based quality parameters, leading to batch-to-batch variation. Recent advancements at Shaanxi New Horizon Biotechnology using enzyme-assisted extraction (cellulase and pectinase pretreatment) have demonstrated 82% polyphenol recovery with 30% reduction in extraction time—a technology now being scaled for commercial production.
Therapeutic Properties and Modern Research Validation
Euryale ferox extract is widely used in TCM formulations for spleen and kidney support. Traditional applications include treatment of chronic diarrhea, excessive leukorrhea, nocturnal enuresis, and premature ejaculation—conditions associated with spleen Qi deficiency and kidney Qi insecurity. Modern pharmacological research has validated several traditional uses: (1) antioxidant activity—Euryale ferox polyphenols demonstrate DPPH radical scavenging IC50 values of 25-35 μg/mL, comparable to green tea extracts; (2) renal protection—animal studies show that Euryale ferox extract reduces urinary albumin excretion and attenuates renal tubular injury in diabetic nephropathy models; and (3) anti-diarrheal effects—polysaccharide fractions inhibit intestinal motility and reduce fecal water content in experimental models. These scientific validations support the ingredient’s transition from traditional use to evidence-based nutraceutical applications.
Industry Segmentation: Product Forms and Applications
The Euryale Ferox Extract market is segmented as below:
Key Players
Shaanxi New Horizon Biotechnology, Xian Tianxingjian Natural Bio-products, Ciyuan Biology, Xi’an Jincuifang Plant Technology Development, Shaanxi Yongyuan Biotechnology, World-Way Biotech, Sanyuan Tianyu Biological Products, Shaanxi Evergreen Herbal Biotech, Baoji Uupanyun Biology, Xian Clover Biotechnology, Shaanxi Sinuote Biotechnology
Segment by Type
- Powder – Dominant form (approximately 75% of market); spray-dried or freeze-dried extract; preferred for capsules, tablets, and powdered beverage mixes
- Liquid – Concentrated solution for liquid nutraceuticals, tinctures, and functional beverages
Segment by Application
- Pharmaceutical – TCM formulations including patent medicines for spleen-kidney support
- Nutraceuticals – Fastest-growing segment; dietary supplements for digestive health, kidney support, and anti-aging
- Food – Functional food ingredients (health porridges, teas, snack bars)
- Others – Cosmetic and personal care applications (antioxidant properties)
Discrete vs. Continuous Manufacturing Perspective in Extract Production
A unique industry observation: discrete manufacturing (e.g., batch-based extraction and drying at smaller producers such as Baoji Uupanyun Biology or Xian Clover Biotechnology) faces batch-to-batch consistency challenges, with polyphenol content varying by ±20-25% between production runs due to variations in raw material quality (seed age, storage conditions) and extraction parameters. In contrast, continuous manufacturing (e.g., automated extraction lines at larger producers like Shaanxi New Horizon Biotechnology) achieves greater standardization, with variation below ±8%, but requires higher capital investment (typically US$ 1.5-3 million for a fully automated line) and minimum production volumes of 15-20 tons annually. This divergence suggests market bifurcation: larger producers serving pharmaceutical and export nutraceutical customers will increasingly adopt continuous processes, while smaller producers serving domestic nutraceutical and food customers will maintain flexible batch operations for shorter runs and customized specifications.
Exclusive Industry Insight: The Renal Health Nutraceutical Segment
While most market analyses treat Euryale ferox extract as a general digestive health ingredient, the fastest-growing and most differentiated segment in H1 2025 is kidney support nutraceuticals targeting the aging population. According to retail sales data from China’s health food channels, Euryale ferox-containing supplements positioned for kidney health grew 28% year-over-year in 2024, significantly outpacing the broader botanical supplement market (12% growth). Key demand drivers include China’s rapidly aging demographic (population aged 60+ reached 297 million in 2024) and increasing awareness of chronic kidney disease, which affects approximately 10% of the global population. Unlike general digestive health supplements where competition is intense and differentiation difficult, kidney health positioning enables premium pricing (20-40% ASP premium) and brand differentiation. Manufacturers with clinical study data supporting renal protection claims—such as reduced urinary albumin excretion or improved estimated glomerular filtration rate (eGFR) biomarkers—capture disproportionate market share. This under-discussed renal health segment represents the primary growth battleground for the next 3-5 years, yet remains absent from most mainstream market analyses.
Policy and Regulatory Environment
The Euryale ferox extract market operates within China’s evolving botanical regulatory framework. Key policies include: (1) NMPA’s 2024 “Catalogue of Health Food Raw Materials,” listing Euryale ferox as a permitted ingredient for spleen and kidney support claims; (2) Chinese Pharmacopoeia (2025 edition) monograph standards for Euryale ferox seed, though extract-specific parameters remain under development; and (3) EU Traditional Herbal Medicinal Products Directive requirements for Euryale ferox-containing products entering European markets. Exporters to the U.S. must comply with FDA Dietary Supplement Health and Education Act (DSHEA) requirements, including cGMP certification and facility registration, with NDI (New Dietary Ingredient) notifications required for novel formulations.
Future Outlook
With increasing consumer awareness of functional botanicals and growing demand for kidney-support and digestive health supplements, Euryale ferox extract is expected to maintain its 5.6% CAGR through 2031. The pharmaceutical segment will remain stable due to established TCM formulation demand, while nutraceuticals—particularly renal health and anti-aging supplements—will drive incremental growth. Risks include raw material supply volatility due to climate factors affecting aquatic cultivation, competition from synthetic alternatives or less expensive botanical substitutes, and evolving international regulatory requirements for traditional herbal ingredients. However, the ingredient’s unique dual positioning in spleen and kidney health—supported by both centuries of traditional use and emerging modern research—ensures continued demand through the forecast period.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
